메뉴 건너뛰기




Volumn 44, Issue 4, 2013, Pages 373-381

Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. Older Adults

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; 13 VALENT PNEUMOCOCCAL VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; 23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

EID: 84884196226     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2012.11.035     Document Type: Article
Times cited : (42)

References (41)
  • 1
    • 84873084648 scopus 로고    scopus 로고
    • CDC. 2012 pink book
    • CDC. 2012 pink book, pneumococcal disease. www.cdc.gov/vaccines/pubs/ pinkbook/downloads/pneumo.pdf.
    • Pneumococcal Disease
  • 2
    • 0031552194 scopus 로고    scopus 로고
    • Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    • CDC
    • CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8):1-24.
    • (1997) MMWR Recomm Rep , vol.46 , Issue.RR-8 , pp. 1-24
  • 4
    • 77956405554 scopus 로고    scopus 로고
    • Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23)
    • CDC. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59(34):1102-6.
    • (2010) MMWR Morb Mortal Wkly Rep , vol.59 , Issue.34 , pp. 1102-1106
  • 5
    • 1242282920 scopus 로고    scopus 로고
    • Pneumococcal polysaccharide vaccine
    • Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed
    • Fedson D, Musher D. Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia: Saunders, 2004.
    • (2004) Philadelphia Saunders
    • Fedson, D.1    Musher, D.2
  • 6
    • 58849088139 scopus 로고    scopus 로고
    • Eff?cacy of pneumococcal vaccination in adults: A meta-analysis
    • Huss A, Scott P, Stuck AE, Trotter C, Egger M. Eff?cacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009;180(1):48-58.
    • (2009) CMAJ , vol.180 , Issue.1 , pp. 48-58
    • Huss, A.1    Scott, P.2    Stuck, A.E.3    Trotter, C.4    Egger, M.5
  • 8
    • 55049089930 scopus 로고    scopus 로고
    • Rationale and design of CAPITA: A RCT of 13-valent conjugated pneumococcal vaccine eff?cacy among older adults
    • Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine eff?cacy among older adults. Neth J Med 2008;66(9):378-83.
    • (2008) Neth J Med , vol.66 , Issue.9 , pp. 378-383
    • Hak, E.1    Grobbee, D.E.2    Sanders, E.A.3
  • 9
    • 82555164974 scopus 로고    scopus 로고
    • Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. CDC
    • Ahmed F, Temte JL, Campos-Outcalt D, Schunemann HJ. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. CDC. Vaccine 2011;29(49):9171-6.
    • (2011) Vaccine , vol.29 , Issue.49 , pp. 9171-9176
    • Ahmed, F.1    Temte, J.L.2    Campos-Outcalt, D.3    Schunemann, H.J.4
  • 10
    • 0036377943 scopus 로고    scopus 로고
    • Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than f?ve years of age for prevention of pneumonia
    • Black SB, Shinef?eld HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than f?ve years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21(9): 810-5.
    • (2002) Pediatr Infect Dis J , vol.21 , Issue.9 , pp. 810-815
    • Black, S.B.1    Shinefeld, H.R.2    Ling, S.3
  • 11
    • 79951812325 scopus 로고    scopus 로고
    • Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: No evidence of hyporesponsiveness
    • Hammitt LL, Bulkow LR, Singleton RJ, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011;29(12):2287-95.
    • (2011) Vaccine , vol.29 , Issue.12 , pp. 2287-2295
    • Hammitt, L.L.1    Bulkow, L.R.2    Singleton, R.J.3
  • 12
    • 27244440305 scopus 로고    scopus 로고
    • Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine
    • Lexau CA, Lynf?eld R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294(16):2043-51.
    • (2005) JAMA , vol.294 , Issue.16 , pp. 2043-2051
    • Lexau, C.A.1    Lynfeld, R.2    Danila, R.3
  • 13
    • 71949103062 scopus 로고    scopus 로고
    • Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine
    • Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32-41.
    • (2010) J Infect Dis , vol.201 , Issue.1 , pp. 32-41
    • Pilishvili, T.1    Lexau, C.2    Farley, M.M.3
  • 14
    • 84856982358 scopus 로고    scopus 로고
    • Adult vaccination coverage-U.S.,2010
    • CDC. Adult vaccination coverage-U.S.,2010. MMWR Morb Mortal Wkly Rep 2012;61(4):66-72.
    • (2012) MMWR Morb Mortal Wkly Rep , vol.61 , Issue.4 , pp. 66-72
  • 15
    • 84863393658 scopus 로고    scopus 로고
    • Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine
    • Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012;307(8):804-12.
    • (2012) JAMA , vol.307 , Issue.8 , pp. 804-812
    • Smith, K.J.1    Wateska, A.R.2    Nowalk, M.P.3    Raymund, M.4    Nuorti, J.P.5    Zimmerman, R.K.6
  • 16
    • 39749203434 scopus 로고    scopus 로고
    • Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis
    • Smith KJ, Zimmerman RK, Lin CJ, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine 2008;26(11):1420-31.
    • (2008) Vaccine , vol.26 , Issue.11 , pp. 1420-1431
    • Smith, K.J.1    Zimmerman, R.K.2    Lin, C.J.3
  • 17
    • 84893064025 scopus 로고    scopus 로고
    • Hyattsville MD National Center for Health Statistics
    • Arias E. U.S. life tables, 2006. National vital statistics reports; vol. 58, no. 21. Hyattsville MD: National Center for Health Statistics, 2010.
    • (2006) National Vital Statistics Reports , vol.58 , Issue.21
    • Arias, E.U.S.1    Tables, L.2
  • 19
    • 0037073586 scopus 로고    scopus 로고
    • Comparing potential benef?ts of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly
    • Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benef?ts of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 2002;21(3-4):303-11.
    • (2002) Vaccine , vol.21 , Issue.3-4 , pp. 303-311
    • Fry, A.M.1    Zell, E.R.2    Schuchat, A.3    Butler, J.C.4    Whitney, C.G.5
  • 21
    • 34047096257 scopus 로고    scopus 로고
    • Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the U.S. A timeseries analysis
    • Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griff?n MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the U.S.: a timeseries analysis. Lancet 2007;369(9568):1179-86.
    • (2007) Lancet , vol.369 , Issue.9568 , pp. 1179-1186
    • Grijalva, C.G.1    Nuorti, J.P.2    Arbogast, P.G.3    Martin, S.W.4    Edwards, K.M.5    Griffn, M.R.6
  • 22
    • 78249253037 scopus 로고    scopus 로고
    • Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the U.S
    • Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the U.S. Vaccine 2010;28(48):7634-43.
    • (2010) Vaccine , vol.28 , Issue.48 , pp. 7634-7643
    • Rubin, J.L.1    McGarry, L.J.2    Strutton, D.R.3
  • 23
    • 77954757935 scopus 로고    scopus 로고
    • Clinical and economic burden of pneumococcal disease in older U.S. Adults
    • Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older U.S. adults. Vaccine 2010;28(31):4955-60.
    • (2010) Vaccine , vol.28 , Issue.31 , pp. 4955-4960
    • Weycker, D.1    Strutton, D.2    Edelsberg, J.3    Sato, R.4    Jackson, L.A.5
  • 24
    • 84860372845 scopus 로고    scopus 로고
    • Aging population and future burden of pneumococcal pneumonia in the U.S
    • Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the U.S. J Infect Dis 2012;205(10):1589-92.
    • (2012) J Infect Dis , vol.205 , Issue.10 , pp. 1589-1592
    • Wroe, P.C.1    Finkelstein, J.A.2    Ray, G.T.3
  • 25
    • 0033585453 scopus 로고    scopus 로고
    • Safety of revaccination with pneumococcal polysaccharide vaccine
    • Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281(3):243-8.
    • (1999) JAMA , vol.281 , Issue.3 , pp. 243-248
    • Jackson, L.A.1    Benson, P.2    Sneller, V.P.3
  • 26
    • 0038470983 scopus 로고    scopus 로고
    • Costeffectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: Role of comorbid conditions and race
    • Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Costeffectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003;138(12):960-8.
    • (2003) Ann Intern Med , vol.138 , Issue.12 , pp. 960-968
    • Sisk, J.E.1    Whang, W.2    Butler, J.C.3    Sneller, V.P.4    Whitney, C.G.5
  • 27
    • 85060902252 scopus 로고    scopus 로고
    • Centers for Medicare & Medicaid Services
    • CPT 90471; Data Year
    • Centers for Medicare & Medicaid Services. Physician Fee Schedule Search (CPT 90471; Data Year: 2006). www.cms.gov/apps/physicianfee-schedule/ search/search-criteria.aspx.
    • (2006) Physician Fee Schedule Search
  • 28
    • 33645235157 scopus 로고    scopus 로고
    • CDC.
    • CDC. CDC Vaccine Price List. www.cdc.gov/vaccines/programs/vfc/awardees/ vaccine-management/price-list/downloads/2006.pdf.
    • CDC Vaccine Price List
  • 29
    • 0028235679 scopus 로고
    • Cost-effectiveness analysis, extended dominance, and ethics: A quantitative assessment
    • Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994;14(3):259-65.
    • (1994) Med Decis Making , vol.14 , Issue.3 , pp. 259-265
    • Cantor, S.B.1
  • 30
    • 41149171625 scopus 로고    scopus 로고
    • What does the value of modern medicine say about the $50000 per qualityadjusted life-year decision rule
    • Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per qualityadjusted life-year decision rule? Med Care 2008;46(4):349-56.
    • (2008) Med Care , vol.46 , Issue.4 , pp. 349-356
    • Braithwaite, R.S.1    Meltzer, D.O.2    Leslie, D.3    Roberts, M.S.4
  • 31
    • 0026575912 scopus 로고
    • How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
    • Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146(4):473-81.
    • (1992) CMAJ , vol.146 , Issue.4 , pp. 473-481
    • Laupacis, A.1    Feeny, D.2    Detsky, A.S.3    Tugwell, P.X.4
  • 32
    • 84871627281 scopus 로고    scopus 로고
    • U.S. Census Bureau
    • U.S. Census Bureau. National Population Estimates for the 2000s. www.census.gov/popest/data/national/asrh/2009/f?les/NC-EST2009-ALLDATA-R-File20. csv.
    • National Population Estimates for the 2000s
  • 33
    • 53349153976 scopus 로고    scopus 로고
    • Indirect effect of 7-valent pneumococcal conjugate vaccineonpneumococcal colonizationamongunvaccinated household members
    • Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccineonpneumococcal colonizationamongunvaccinated household members. Clin Infect Dis 2008;47(8):989-96.
    • (2008) Clin Infect Dis , vol.47 , Issue.8 , pp. 989-996
    • Millar, E.V.1    Watt, J.P.2    Bronsdon, M.A.3
  • 34
    • 33748323238 scopus 로고    scopus 로고
    • Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: Updated analysis using World Health Organization standardized interpretation of chest radiographs
    • Hansen J, Black S, Shinef?eld H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006;25(9):779-81.
    • (2006) Pediatr Infect Dis J , vol.25 , Issue.9 , pp. 779-781
    • Hansen, J.1    Black, S.2    Shinefeld, H.3
  • 36
    • 0342614917 scopus 로고    scopus 로고
    • Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine
    • Zielen S, Buhring I, Strnad N, Reichenbach J, Hofmann D. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun 2000;68(3):1435-40.
    • (2000) Infect Immun , vol.68 , Issue.3 , pp. 1435-1440
    • Zielen, S.1    Buhring, I.2    Strnad, N.3    Reichenbach, J.4    Hofmann, D.5
  • 37
    • 34247218436 scopus 로고    scopus 로고
    • Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    • Jackson LA, Neuzil KM, Nahm MH, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007;25(20):4029-37.
    • (2007) Vaccine , vol.25 , Issue.20 , pp. 4029-4037
    • Jackson, L.A.1    Neuzil, K.M.2    Nahm, M.H.3
  • 38
    • 75749150864 scopus 로고    scopus 로고
    • Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middleaged and older adults
    • Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middleaged and older adults. J Infect Dis 2010;201(4):516-24.
    • (2010) J Infect Dis , vol.201 , Issue.4 , pp. 516-524
    • Musher, D.M.1    Manof, S.B.2    Liss, C.3
  • 39
    • 72849118939 scopus 로고    scopus 로고
    • The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years
    • Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009;49(9): 1318-25.
    • (2009) Clin Infect Dis , vol.49 , Issue.9 , pp. 1318-1325
    • Goldblatt, D.1    Southern, J.2    Andrews, N.3
  • 40
    • 67349118429 scopus 로고    scopus 로고
    • Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: A cost-effectiveness analysis
    • Smith KJ, Zimmerman RK, Nowalk MP, Roberts MS. Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: a cost-effectiveness analysis. Vaccine 2009;27(24): 3159-64.
    • (2009) Vaccine , vol.27 , Issue.24 , pp. 3159-3164
    • Smith, K.J.1    Zimmerman, R.K.2    Nowalk, M.P.3    Roberts, M.S.4
  • 41
    • 79954645991 scopus 로고    scopus 로고
    • Healthcare utilization and cost of pneumococcal disease in the U.S
    • Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the U.S. Vaccine 2011;29(18):3398-412.
    • (2011) Vaccine , vol.29 , Issue.18 , pp. 3398-3412
    • Huang, S.S.1    Johnson, K.M.2    Ray, G.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.